JANUARY 1 – MARCH 31 2008
• Net sales for the period amounted to SEK 15.6 M (16.1)
• Profit after tax was SEK 3.1 M (5.2)
• Earnings per share amounted to SEK 0.27 (0.46)
• Operating profit amounted to SEK 3.6 M (7.1)
• Cash flow from operating activities amounted to SEK 1.2 M (13.4)
• The first revenues were recorded for COMPASS® and the agreement with IBA Dosimetry was expanded
AFTER THE END OF THE REPORTING PERIOD
• Release of first product from Varian collaboration postponed
• Negotiations in final stages with Philips regarding development of a new product for the new revolutionary treatment method VMAT
• As a result of the market driven prioritization of VMAT, the first product release within adaptive radiation therapy will been delayed
”We are currently finalizing the negotiations with Philips regarding a new product for VMAT which is a new exciting area with very large potential. However, this also means that the first product release from the collaboration with Philips regarding adaptive radiotherapy will be postponed,” says Johan Löf, CEO of RaySearch.
“The COMPASS® collaboration with IBA Dosimetry has now started to generate revenues. We have also expanded the COMPASS® collaboration with a new product that, together with the new Philips product, further strengthens our broad growth platform.”
”The first product release from the Varian collaboration has been postponed until next year. The delay is not due to any technical reasons” concludes Johan Löf.
FOR FURTHER INFORMATION, CONTACT:
Johan Löf, President and CEO
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com
RaySearch Laboratories AB (publ)
Corp. Reg. No. 556322-6157
Sveavägen 25
SE-111 34 Stockholm
Financial Reports
